139 related articles for article (PubMed ID: 10738247)
1. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors.
Hanemaaijer R; Verheijen JH; Maguire TM; Visser H; Toet K; McDermott E; O'Higgins N; Duffy MJ
Int J Cancer; 2000 Apr; 86(2):204-7. PubMed ID: 10738247
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of plasma matrix metalloproteases 2, 3, 9 in breast carcinomas and fibroadenomas].
Solai F; Nardo T; Patrizi G; Annessi M; Santulli M; Amabile MI; Vasaturo F
G Chir; 2010; 31(8-9):365-7. PubMed ID: 20843437
[TBL] [Abstract][Full Text] [Related]
3. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions.
Singer CF; Kronsteiner N; Marton E; Kubista M; Cullen KJ; Hirtenlehner K; Seifert M; Kubista E
Breast Cancer Res Treat; 2002 Mar; 72(1):69-77. PubMed ID: 12000221
[TBL] [Abstract][Full Text] [Related]
4. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
5. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas.
Iwata H; Kobayashi S; Iwase H; Masaoka A; Fujimoto N; Okada Y
Jpn J Cancer Res; 1996 Jun; 87(6):602-11. PubMed ID: 8766524
[TBL] [Abstract][Full Text] [Related]
6. Augmented release of matrix metalloproteinase-9 by PKC activation in organotypic cultures of human breast cancer and adjacent normal breast tissue and fibroadenoma.
Wu TT; Tsai JH; Tsai JH; Kuo SJ; Yu SY; Huang CY; Hsieh HY; Hsieh YS; Liu JY
Chin J Physiol; 2004 Jun; 47(2):73-8. PubMed ID: 15481789
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
[TBL] [Abstract][Full Text] [Related]
8. Zymographic analysis of circulating and tissue forms of colon carcinoma gelatinase A (MMP-2) and B (MMP-9) separated by mono- and two-dimensional electrophoresis.
Pucci-Minafra I; Minafra S; La Rocca G; Barranca M; Fontana S; Alaimo G; Okada Y
Matrix Biol; 2001 Nov; 20(7):419-27. PubMed ID: 11691582
[TBL] [Abstract][Full Text] [Related]
9. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.
Jones JL; Glynn P; Walker RA
J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569
[TBL] [Abstract][Full Text] [Related]
10. The activity of matrix metalloproteinases (MMPS) and tissue inhibitors of metalloproteinases (TIMPs) in mammary tumors of dogs and rats.
Kawai K; Uetsuka K; Doi K; Nakayama H
J Vet Med Sci; 2006 Feb; 68(2):105-11. PubMed ID: 16520530
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
Das S; Amin SA; Jha T
Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
[TBL] [Abstract][Full Text] [Related]
13. Values of MMP-2 and MMP-9 in tumor tissue of basal-like breast cancer patients.
Radenkovic S; Konjevic G; Jurisic V; Karadzic K; Nikitovic M; Gopcevic K
Cell Biochem Biophys; 2014 Jan; 68(1):143-52. PubMed ID: 23812723
[TBL] [Abstract][Full Text] [Related]
14. [A quantitative study of matrix metalloproteinases in proliferative vitreoretinopathy].
Zeng J; Jiang D; Zhu X; Tang L
Yan Ke Xue Bao; 2003 Jun; 19(2):130-2. PubMed ID: 12870353
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical study of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinase 1 in benign and malignant breast tissue--strong expression in intraductal carcinomas of the breast.
Rahko E; Kauppila S; Pääkkö P; Blanco G; Apaja-Sarkkinen M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Jukkola A
Tumour Biol; 2009; 30(5-6):257-64. PubMed ID: 19887890
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
[TBL] [Abstract][Full Text] [Related]
17. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
18. Clinical and prognostic role of matrix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: A review.
Daniele A; Abbate I; Oakley C; Casamassima P; Savino E; Casamassima A; Sciortino G; Fazio V; Gadaleta-Caldarola G; Catino A; Giotta F; De Luca R; Divella R
Int J Biochem Cell Biol; 2016 Aug; 77(Pt A):91-101. PubMed ID: 27267661
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases 2, 7, and 9 in tumors and sera of patients with breast cancer.
Katunina AI; Gershtein ES; Ermilova VD; Tereshkina IV; Nazarenko AY; Tyleuova AA; Dvorova EK; Karabekova ZK; Gritskevich MV; Berezov TT
Bull Exp Biol Med; 2011 Jul; 151(3):359-62. PubMed ID: 22451887
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases participate in osteosarcoma invasion.
Bjørnland K; Flatmark K; Pettersen S; Aaasen AO; Fodstad O; Maelandsmo GM
J Surg Res; 2005 Aug; 127(2):151-6. PubMed ID: 16083752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
